BIOS ERRORS
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%
The FPIs that were selling in the Indian market all these months mostly owned large-cap stocks. And as they sold them, it was that segment which bore the brunt of the selling. The same logic will operate in reverse as they start buying, focusing once again on the safer and more liquid large-cap stocks.
Short-term headwinds, yes; owning the ecosystem is better: 20 healthcare stocks with downside risk of 23% to upside potential of 41%
The healthcare sector is under scrutiny. The issue is pricing: What medicines cost and on what hospitals and the rest of the health ecosystem charge. And both the government and the courts have stepped in. At one level, that is not entirely a bad thing. Check out Stock Reports Plus, powered by Refinitiv, for price targets of over 4,000 listed stocks along with detailed company analysis focusing on five key components – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. SR+ Reports is a complimentary offering to ETPrime members.
These large-, mid- and small-cap stocks can give more than 20% return in 1 year, according to analysts
Here’s one thing that is worth clarifying, because it is in the headlines. Large global technology companies have been announcing heavy spending on AI, and there has been some correction in those stocks because of it. It is natural to worry that this will spill over into the Indian market. It most likely will not.
Sugar stocks: Short-term pain is real; has the long-term case broken? 7 stocks from the sugar-ethanol ecosystem
Though this year's ethanol tender leaves sugar out, the long-term blending roadmap still points to rising ethanol use. The move is aimed at a short-term sugar-supply problem, not at ethanol itself. Check out Stock Reports Plus, powered by Refinitiv, for price targets of over 4,000 listed stocks along with detailed company analysis focusing on five key components – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardized scores. SR+ Reports is a complimentary offering to ETPrime members.
These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analysts
The last few weeks have made one thing clear. Oil prices, US bond yields, corporate earnings, and the state of the world – all point the same way. So, the market is more likely to stay in this jumpy and uncertain mood for quite some time. But then there is something called history, and it provides some interesting lessons.
Fertiliser stocks: Combination of strong headwinds and structural repair. Who will win? 9 stocks, 4 with upside potential of up to 31%
For the better part of a decade now, every time this critical sector has run into trouble, the government has stepped in. The clean-up began with small steps. The mandatory coating of urea with neem was an early one. It was a measure that was not financial on the face of it; but it changed the sector’s economics by stopping the diversion of subsidised fertiliser to other uses.
- Go To Page 1
Rs 250 investment, Rs 90 lakh annual revenue. How Kerala woman turned mushroom farming on her balcony into a thriving business
With Rs 250 as an investment, a Kerala couple, Shije and Thankachan started mushroom farming in their home balcony. Initially, they faced humble profits, making between Rs 2,000 to Rs 5,000 per month. Cut to a few years, their venture has blossomed into a bio-high-tech mushroom farm producing impressive annual revenues of Rs 80-90 lakh. Now they aspire to double this amount.
These large- and mid-cap stocks can give more than 20% return in 1 year, according to analysts
The mayhem in the market is likely to continue, at least for the short-term. Nothing has changed in terms of the known headwinds: The US-Iran war continues in fits and starts, oil prices are still elevated, US bond rates remain high, and global supply chains continue to be disrupted. With the calendar year-end approaching, however, there is a technical factor that has entered the mix.
When nothing is cheap, winners may come from any corner: 19 stocks with downside to upside potential of -28% to plus 22%
Because each pharma company took a different road, they no longer rise and fall together. Where any one of them stands in 10 years depends on what it chose in the last five or six. So, one name can do wonderfully while the one sitting next to it does very little. Stock Reports Plus, powered by Refinitiv, is a comprehensive report that evaluates five key components of 4,000+ listed stocks – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. The simple average of the above-mentioned five component ratings is normally distributed to reach an average score.
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 20%
In times like these, the market will have its green and red days. What matters, however, is not the colour of a single day, but the things underneath it: The central bank, the fund flows, and, above all, corporate earnings. Watch those, stay patient, and forget the daily noise.
The debate is settling, the business is moving. Time to look at a larger set? 9 sugar-ethanol ecosystem stocks for the watchlist
A new fuel programme is not an easy thing to implement. And it sparks intense debate. Ethanol, for instance, has taken over two decades to reach some scale, and it has been dogged by controversies. But the noise is now dying down as it meets targets that were said to be impossible to achieve. Check out Stock Reports Plus, powered by Refinitiv, for price targets of over 4,000 listed stocks along with detailed company analysis focusing on five key components – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. SR+ Reports is a complimentary offering to ETPrime members.
These large- and mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos have upside potential of up to 25%, according to analysts
Talk of tariffs, especially steep ones, makes the market nervous. Which is exactly why the next few trading sessions are critical, and why being in a hurry to take any market-related decision is the one thing to avoid right now. It is better to be cautious, to wait and watch. And let the picture become a little clearer before you act.
These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analysts
As an investor, what you need to do at this point of time is this: A bit of extra work in terms of stock-picking so that you avoid anxiety during future corrective phases in the market. And there should not be any doubt that, given the current geopolitical conditions, there will be many more corrective phases.
In 2024, University of Chicago researchers turned discarded bio-oil char into graphite; 8 hours of cooling made crystals 5 times thicker and over 15 times wider
US researchers have developed a method to convert plant waste into high-quality graphite. This breakthrough offers a potential domestic source for a critical battery component. The new process involves slow cooling of biochar, creating larger graphite crystals. This sustainable alternative could reduce reliance on imported graphite for electronics. Further development is needed to scale up production and lower costs for commercial use.
These large- and mid-cap stocks can give more than 20% return in 1 year, according to analysts
The Indian market was under pressure on Thursday, particularly at the index level. Rising crude-oil prices are an obvious concern, but domestic factors like selling and market repricing in select sectors may also be beginning to impact sentiment. Also, are there early indications that Indian equities will be charting their own course as compared to what is happening in the global markets?
For investors who can bear the noise created by Trump and missiles: 5 mid-cap stocks with upside potential of up to 22%
After a lull, things are again heating up in the US-Iran war. From sanctions, which drew the ire of China, to missiles, which are again flying in the Gulf skies. With crude oil prices heading north, another round of volatility is hitting the Indian market. But does that mean you cannot invest at this time? You can. But there is something really important to consider before deploying your hard-earned money.
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of more than 20%
We normally don’t dwell on F&Os in this space. However, it is good to know that, in the current circumstances, an upmove in the indices and certain key stocks could be because of short-covering. They are usually sharp and may seem like a market recovery, but may not actually be one. Any sustainable recovery will have market breadth; without that, it is suspect.
The emperor's new biomarker? Another wearable for us to evaluate
A new wearable biomarker, 'Entropy,' measuring body energy consumption, has stirred the bio-hacking community. While the name is catchy, the article questions its scientific accuracy and the proven benefits of such tracking, drawing parallels to existing wearables with questionable efficacy. The author highlights human bias towards action and the allure of new tech, suggesting 'Fugacity' as a more fitting, albeit esoteric, name for future biomarkers.
Nearly 1.46 lakh AI-hallucinated references entered scientific papers in 2025: Study
A surge in AI-generated hallucinated citations has infiltrated scientific literature, with over 146,000 fabricated references appearing in 2025 alone. Studies reveal these fake citations are bypassing peer review and appearing in published journals, disproportionately affecting less experienced authors and solo researchers. Safeguards are proving inadequate, raising concerns about the integrity of scientific records.
Battlefield 6 Open Beta on PC: How to turn on secure boot in multiplayer shooter game; follow the steps to enter warfare
Battlefield 6's beta version has launched ahead of its October 2025 release, requiring players to enable Secure Boot. This security feature, crucial for EA's anti-cheat measures, ensures only safe software loads during PC startup. Gamers encountering errors are guided to activate Secure Boot through their BIOS settings, enhancing game security and fairness.
PM Kisan Aadhaar name mismatch: You will get Rs 2,000 instalment only if Aadhaar name matches
Farmers are anticipating the 20th PM-Kisan installment, expected in early July 2025. Beneficiaries must ensure their names match Aadhaar records to avoid payment delays. The government facilitates name corrections through face authentication via the PM-Kisan Mobile App or bio-authentication at CSC centers, urging farmers to verify their status and complete eKYC.
Microsoft-CrowdStrilke outage: Why were all computers not affected?
The recent Microsoft outage, which disrupted services worldwide including Microsoft 365, was primarily caused by a conflict between Microsoft's software and Cloudstrike's Falcon Sensor endpoint protection. This issue led to widespread disruptions in various sectors such as airlines, banking, media, and healthcare. However, not all systems were affected; only those using Cloudstrike’s Falcon Sensor experienced problems.
US puts J&J in charge of plant that botched Covid vax, removes AstraZeneca
Johnson & Johnson, with help from the Biden administration, is taking over a Baltimore vaccine production facility that was the site of a major manufacturing error last month and moving production of material for a second company’s shot to minimise the risk of another mistake.
EU regulator is considering Oxford-AstraZeneca vaccine
The EU regulator said it received a request for the vaccine to be green-lighted under an expedited process and that it could be approved by Jan. 29 "provided that the data submitted on the quality, safety and efficacy of the vaccine are sufficiently robust and complete."
European Union regulator gets request to approve AstraZeneca-Oxford COVID-19 vaccine
In a statement Tuesday, the EU regulator said it has received a request for the vaccine to be green-lighted under an expedited process and that it could be approved by Jan. 29 during an EMA meeting, "provided that the data submitted on the quality, safety and efficacy of the vaccine are sufficiently robust and complete."
UK appoints vaccines minister to oversee COVID inoculations
Prime Minister Boris Johnson said Conservative lawmaker Nadhim Zahawi will oversee the country's biggest vaccine program in decades. The UK medicines regulator is currently assessing two vaccines — one developed by Pfizer and BioNTech, the other by Oxford University and AstraZeneca — to see if they are safe and effective.
Questions over AstraZeneca's COVID-19 vaccine data risk delaying approval
Several scientists have raised doubts about the robustness of results showing the shot was 90% effective in a sub-group of trial participants who, by error initially, received a half dose followed by a full dose.
AstraZeneca faces more vaccine questions after manufacturing error
While an announcement Monday by Astra and Oxford showed their shot was 70% effective on average in a late-stage study, the scant details released by the U.K. partners have sparked worries about whether regulators would clear it. In a later statement, Oxford said a difference in manufacturing processes led to some participants being given a half dose instead of a full one.
Novel coronavirus mutations may not make it more infectious: Study
Coronaviruses, like other RNA viruses, can develop mutations in three different ways: by mistake from copying errors during viral replication, through interactions with other viruses infecting the same cell, or they can be induced by RNA modification systems which are part of host immunity, the researchers explained.
Load More
